Mercy BioAnalytics Receives FDA Approval to Initiate Prospective Pivotal Study of Evident™Ovarian Cancer Screening Test

RegulatoryapprovedEvident™Positive

AI Analysis

Summary

Mercy BioAnalytics received FDA Investigational Device Exemption (IDE) approval to initiate the SOARA prospective pivotal clinical validation study for its Evident™ ovarian cancer screening test. The approval enables the company to proceed with the pivotal study following Institutional Review Board approval.

Clinical Trial Data

Phase

pivotal

Outcome Details

FDA IDE approval to initiate prospective pivotal clinical validation study

Importance:7/10

Sentiment:

0.85

FDA approvalovarian cancerscreening testIDE approvalpivotal study

Read the original article

Published by PR Newswire Pharma on September 21, 2026 5:27 PM

Read Original